General Information of Drug (ID: DMSDBPG)

Drug Name
KN046 Drug Info
Indication
Disease Entry ICD 11 Status REF
Non-small-cell lung cancer 2C25.Y Phase 3 [1]
Cross-matching ID
TTD Drug ID
DMSDBPG

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cytotoxic T-lymphocyte protein 4 (CTLA-4) TTI2S1D CTLA4_HUMAN Inhibitor [2]
Programmed cell death 1 ligand 1 (PD-L1) TT8ZLTI PD1L1_HUMAN Inhibitor [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cytotoxic T-lymphocyte protein 4 (CTLA-4) DTT CTLA4 4.684 5.333 3.954 2.293
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Non-small-cell lung cancer
ICD Disease Classification 2C25.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Programmed cell death 1 ligand 1 (PD-L1) DTT CD274 4.38E-07 0.37 2.1
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04474119) KN046 in Subjects With Advanced Squamous Non-small Cell Lung Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Alphamab Oncology.